Immune recovery following autologous hematopoietic stem cell transplantation in HIV-related lymphoma patients on the BMT CTN 0803/AMC 071 trial Journal Article


Authors: Shindiapina, P.; Pietrzak, M.; Seweryn, M.; McLaughlin, E.; Zhang, X.; Makowski, M.; Ahmed, E. H.; Schlotter, S.; Pearson, R.; Kitzler, R.; Mozhenkova, A.; Le-Rademacher, J.; Little, R. F.; Akpek, G.; Ayala, E.; Devine, S. M.; Kaplan, L. D.; Noy, A.; Popat, U. R.; Hsu, J. W.; Morris, L. E.; Mendizabal, A. M.; Krishnan, A.; Wachsman, W.; Williams, N.; Sharma, N.; Hofmeister, C. C.; Forman, S. J.; Navarro, W. H.; Alvarnas, J. C.; Ambinder, R. F.; Lozanski, G.; Baiocchi, R. A.
Article Title: Immune recovery following autologous hematopoietic stem cell transplantation in HIV-related lymphoma patients on the BMT CTN 0803/AMC 071 trial
Abstract: We report a first in-depth comparison of immune reconstitution in patients with HIV-related lymphoma following autologous hematopoietic cell transplant (AHCT) recipients (n=37, lymphoma, BEAM conditioning), HIV(-) AHCT recipients (n=30, myeloma, melphalan conditioning) at 56, 180, and 365 days post-AHCT, and 71 healthy control subjects. Principal component analysis showed that immune cell composition in HIV(+) and HIV(-) AHCT recipients clustered away from healthy controls and from each other at each time point, but approached healthy controls over time. Unsupervised feature importance score analysis identified activated T cells, cytotoxic memory and effector T cells [higher in HIV(+)], and naïve and memory T helper cells [lower HIV(+)] as a having a significant impact on differences between HIV(+) AHCT recipient and healthy control lymphocyte composition (p<0.0033). HIV(+) AHCT recipients also demonstrated lower median absolute numbers of activated B cells and lower NK cell sub-populations, compared to healthy controls (p<0.0033) and HIV(-) AHCT recipients (p<0.006). HIV(+) patient T cells showed robust IFNγ production in response to HIV and EBV recall antigens. Overall, HIV(+) AHCT recipients, but not HIV(-) AHCT recipients, exhibited reconstitution of pro-inflammatory immune profiling that was consistent with that seen in patients with chronic HIV infection treated with antiretroviral regimens. Our results further support the use of AHCT in HIV(+) individuals with relapsed/refractory lymphoma.
Keywords: multiple myeloma; non-hodgkin lymphoma; human immunodeficiency virus (hiv); hematopoeietic stem cell transplantation; hodgkin lymphoma (hl)
Journal Title: Frontiers in Immunology
Volume: 12
ISSN: 1664-3224
Publisher: Frontiers Media S.A.  
Date Published: 2021-09-03
Start Page: 700045
Language: English
DOI: 10.3389/fimmu.2021.700045
PROVIDER: scopus
PMCID: PMC8446430
PUBMED: 34539628
DOI/URL:
Notes: Article -- Export Date: 1 October 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ariela Noy
    352 Noy